Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Key Points
Higher HER2 scores correlate with increased protein expression of cell surface antigens in prostate cancer, enhancing treatment pathways.
The analysis shows distinct patterns of HER2 expression in prostate cancer versus urothelial cancer, indicating varied responses to therapies.
Utilizing immunohistochemistry (IHC), the study evaluates protein expression levels in cancerous tissues, providing a basis for therapeutic strategies.
Further research is needed to establish the efficacy of HER2-targeted therapies across different cancer types, especially in metastatic settings.
Abstract
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in (A) prostate cancer and (B) urothelial cancer.